Market Closed -
Nasdaq Copenhagen
15:59:58 30/04/2024 BST
|
5-day change
|
1st Jan Change
|
633
DKK
|
+2.51%
|
|
+8.86%
|
+69.61%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,472
|
8,766
|
6,271
|
10,366
|
21,785
|
39,420
|
-
|
-
|
Enterprise Value (EV)
1 |
7,092
|
7,638
|
5,364
|
9,712
|
20,152
|
36,807
|
36,734
|
36,268
|
P/E ratio
|
-13.9
x
|
-10
x
|
-6.11
x
|
-7.74
x
|
-30
x
|
-103
x
|
-730
x
|
-140
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
205
x
|
24.8
x
|
21.4
x
|
99.7
x
|
63.6
x
|
56.8
x
|
34.6
x
|
26.8
x
|
EV / Revenue
|
172
x
|
21.6
x
|
18.3
x
|
93.4
x
|
58.8
x
|
53
x
|
32.2
x
|
24.7
x
|
EV / EBITDA
|
-12.3
x
|
-10.2
x
|
-5.3
x
|
-13.5
x
|
-36.8
x
|
-154
x
|
-1,262
x
|
-527
x
|
EV / FCF
|
-16.5
x
|
-10.7
x
|
-4.35
x
|
-10.2
x
|
-46.1
x
|
-135
x
|
89
x
|
143
x
|
FCF Yield
|
-6.07%
|
-9.34%
|
-23%
|
-9.82%
|
-2.17%
|
-0.74%
|
1.12%
|
0.7%
|
Price to Book
|
6.82
x
|
6.89
x
|
6.83
x
|
11.4
x
|
13.7
x
|
13.2
x
|
12.4
x
|
11.8
x
|
Nbr of stocks (in thousands)
|
35,990
|
39,735
|
43,216
|
51,470
|
58,374
|
62,275
|
-
|
-
|
Reference price
2 |
235.4
|
220.6
|
145.1
|
201.4
|
373.2
|
633.0
|
633.0
|
633.0
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
41.3
|
353.3
|
292.6
|
104
|
342.8
|
694
|
1,140
|
1,470
|
EBITDA
1 |
-574.3
|
-749.7
|
-1,012
|
-719.2
|
-547.2
|
-239.7
|
-29.11
|
-68.78
|
EBIT
1 |
-587.9
|
-792.4
|
-1,052
|
-837.2
|
-572.2
|
-451.2
|
-143.3
|
163.3
|
Operating Margin
|
-1,423.49%
|
-224.27%
|
-359.7%
|
-805.06%
|
-166.94%
|
-65.02%
|
-12.57%
|
11.11%
|
Earnings before Tax (EBT)
1 |
-576.7
|
-839.7
|
-1,027
|
-972
|
-708.9
|
-292.1
|
106.7
|
536.9
|
Net income
1 |
-571.5
|
-846.7
|
-1,018
|
-1,202
|
-703.7
|
-383.1
|
-272.2
|
-321.8
|
Net margin
|
-1,383.88%
|
-239.65%
|
-348.01%
|
-1,156.05%
|
-205.3%
|
-55.2%
|
-23.88%
|
-21.9%
|
EPS
2 |
-16.91
|
-22.07
|
-23.75
|
-26.02
|
-12.44
|
-6.138
|
-0.8673
|
-4.529
|
Free Cash Flow
1 |
-430.5
|
-713.8
|
-1,234
|
-953.9
|
-436.9
|
-273.2
|
412.7
|
253.7
|
FCF margin
|
-1,042.35%
|
-202.02%
|
-421.82%
|
-917.35%
|
-127.46%
|
-39.36%
|
36.2%
|
17.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
106.4
|
54.02
|
50.79
|
50.21
|
43.71
|
23.92
|
13.63
|
10.41
|
295.5
|
23.24
|
3.339
|
9.104
|
47.88
|
198.7
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-211.8
|
-289.7
|
-343.4
|
-293.3
|
-162.1
|
-241
|
-168.7
|
-195.4
|
45.28
|
-253.5
|
-192.6
|
-195.6
|
-168.1
|
-325.7
|
-324.6
|
Operating Margin
|
-199.05%
|
-536.42%
|
-676.17%
|
-584.12%
|
-370.76%
|
-1,007.18%
|
-1,237.69%
|
-1,877.25%
|
15.32%
|
-1,090.94%
|
-5,769.2%
|
-2,148.12%
|
-350.97%
|
-163.88%
|
-
|
Earnings before Tax (EBT)
1 |
-195.7
|
-285.8
|
-210.4
|
-488.5
|
-153.7
|
-322.4
|
-195.3
|
-321
|
72.83
|
-265.3
|
-252.8
|
-262.8
|
-272.7
|
-307.2
|
-
|
Net income
1 |
-198.9
|
-280.3
|
-222.8
|
-488.5
|
-148.3
|
-342.4
|
-193.6
|
-319.5
|
74.14
|
-264.8
|
-177.6
|
-186.2
|
-195.1
|
-372.9
|
-337.1
|
Net margin
|
-186.91%
|
-518.86%
|
-438.79%
|
-972.97%
|
-339.35%
|
-1,431.34%
|
-1,420.84%
|
-3,070.07%
|
25.09%
|
-1,139.44%
|
-5,318.96%
|
-2,045.2%
|
-407.44%
|
-187.61%
|
-
|
EPS
2 |
-4.610
|
-6.490
|
-5.160
|
-11.04
|
-3.210
|
-6.740
|
-3.760
|
-5.500
|
1.230
|
-4.600
|
-4.360
|
-4.465
|
-4.690
|
-5.075
|
-5.340
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
10/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
01/03/23
|
11/05/23
|
17/08/23
|
09/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,381
|
1,127
|
907
|
654
|
1,633
|
2,613
|
2,686
|
3,152
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-430
|
-714
|
-1,234
|
-954
|
-437
|
-273
|
413
|
254
|
ROE (net income / shareholders' equity)
|
-48.5%
|
-68.5%
|
-94.4%
|
-138%
|
-58.4%
|
24.8%
|
-4.31%
|
30.7%
|
ROA (Net income/ Total Assets)
|
-40.4%
|
-50.4%
|
-53.2%
|
-
|
-
|
21%
|
1.99%
|
29%
|
Assets
1 |
1,415
|
1,681
|
1,915
|
-
|
-
|
-1,822
|
-13,671
|
-1,108
|
Book Value Per Share
2 |
34.50
|
32.00
|
21.30
|
17.70
|
27.30
|
48.10
|
51.00
|
53.60
|
Cash Flow per Share
2 |
-12.10
|
-17.90
|
-28.30
|
-20.40
|
-7.520
|
-10.40
|
9.130
|
-4.730
|
Capex
1 |
21
|
25
|
22.1
|
11.7
|
11.2
|
9.32
|
10.9
|
13.6
|
Capex / Sales
|
50.93%
|
7.09%
|
7.57%
|
11.26%
|
3.28%
|
1.34%
|
0.96%
|
0.92%
|
Announcement Date
|
11/03/20
|
11/03/21
|
10/03/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Average target price
782
DKK Spread / Average Target +23.54% Consensus |
1st Jan change
|
Capi.
|
---|
| +69.61% | 5.65B | | -3.46% | 102B | | +1.41% | 96.09B | | +2.13% | 22.28B | | -15.84% | 21.4B | | -9.21% | 18.14B | | -39.98% | 17.02B | | -14.65% | 16.09B | | +4.39% | 13.83B | | +31.35% | 11.97B |
Bio Therapeutic Drugs
|